NCT01533922 - Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients | Biotech Hunter

Enrollment

295

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Placebo

placebo matching tiotropium + olodaterol FDC

DRUG

Tiotropium

Tiotropium 5 mcg once daily

DRUG

Olodaterol

Olodaterol 5 mcg once daily

DRUG

tiotropium + olodaterol

tiotropium + olodaterol 5 mcg once daily

DRUG

Tiotropium + Olodaterol

Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily

DEVICE

Respimat

Respimat inhaler

Trial Locations (44)

Unknown

1237.13.01302 Boehringer Ingelheim Investigational Site, Torrance

1237.13.01308 Boehringer Ingelheim Investigational Site, Hartford

1237.13.01304 Boehringer Ingelheim Investigational Site, Livonia

1237.13.01307 Boehringer Ingelheim Investigational Site, Pittsburgh

1237.13.01305 Boehringer Ingelheim Investigational Site, Easley

1237.13.01301 Boehringer Ingelheim Investigational Site, Greenville

1237.13.01303 Boehringer Ingelheim Investigational Site, Spartanburg

1237.13.01306 Boehringer Ingelheim Investigational Site, Richmond

1237.13.54301 Boehringer Ingelheim Investigational Site, Capital Federal

1237.13.54302 Boehringer Ingelheim Investigational Site, Mar del Plata

1237.13.61306 Boehringer Ingelheim Investigational Site, Concord

1237.13.61301 Boehringer Ingelheim Investigational Site, Daw Park

1237.13.61305 Boehringer Ingelheim Investigational Site, Toorak Gardens

1237.13.61304 Boehringer Ingelheim Investigational Site, Footscray

1237.13.61302 Boehringer Ingelheim Investigational Site, Prahran

1237.13.43303 Boehringer Ingelheim Investigational Site, Linz

1237.13.43301 Boehringer Ingelheim Investigational Site, Thalheim bei Wels

1237.13.32302 Boehringer Ingelheim Investigational Site, Brussels

1237.13.32303 Boehringer Ingelheim Investigational Site, Edegem

1237.13.32305 Boehringer Ingelheim Investigational Site, Jambes

1237.13.32304 Boehringer Ingelheim Investigational Site, Lanaken

1237.13.32301 Boehringer Ingelheim Investigational Site, Leuven

1237.13.11302 Boehringer Ingelheim Investigational Site, Hamilton

1237.13.11303 Boehringer Ingelheim Investigational Site, Kingston

1237.13.11304 Boehringer Ingelheim Investigational Site, Saskatoon

1237.13.56301 Boehringer Ingelheim Investigational Site, Chile

1237.13.56302 Boehringer Ingelheim Investigational Site, Santiago

1237.13.49302 Boehringer Ingelheim Investigational Site, Berlin

1237.13.49307 Boehringer Ingelheim Investigational Site, Dortmund

1237.13.49304 Boehringer Ingelheim Investigational Site, Frankfurt

1237.13.49301 Boehringer Ingelheim Investigational Site, Halle

1237.13.49303 Boehringer Ingelheim Investigational Site, Hanover

1237.13.49305 Boehringer Ingelheim Investigational Site, Lübeck

1237.13.39302 Boehringer Ingelheim Investigational Site, Genova

1237.13.39304 Boehringer Ingelheim Investigational Site, Parma

1237.13.39303 Boehringer Ingelheim Investigational Site, Pavia

1237.13.39305 Boehringer Ingelheim Investigational Site, Pavullo Nel Frignano (mo)

1237.13.39301 Boehringer Ingelheim Investigational Site, Pisa

1237.13.39312 Boehringer Ingelheim Investigational Site, Pisa

1237.13.39310 Boehringer Ingelheim Investigational Site, Roma

1237.13.39308 Boehringer Ingelheim Investigational Site, Sesto S. Giovanni (mi)

1237.13.39306 Boehringer Ingelheim Investigational Site, Trieste

1237.13.64302 Boehringer Ingelheim Investigational Site, Christchurch

1237.13.64301 Boehringer Ingelheim Investigational Site, Greenlane East Auckland NZ